transitional cell carcinoma
Recently Published Documents


TOTAL DOCUMENTS

4358
(FIVE YEARS 196)

H-INDEX

100
(FIVE YEARS 3)

2021 ◽  
Vol 15 (6) ◽  
pp. 331-336
Author(s):  
Pankaj Kumar Singh ◽  
Madan Lal Brahma Bhatt ◽  
Prabhat Singh ◽  
Srikanta Kumar rath ◽  
Diwakar Dalela ◽  
...  

In Vivo ◽  
2021 ◽  
Vol 36 (1) ◽  
pp. 170-179
Author(s):  
SUHAYLA ALNAJJAR ◽  
INGO NOLTE ◽  
JAN TORBEN SCHILLE ◽  
SINA SENDER ◽  
NARES TRAKOOLJU ◽  
...  

2021 ◽  
Vol 75 ◽  
pp. 123-127
Author(s):  
Konrad Majcherczyk ◽  
Mateusz Marcinek ◽  
Marcel Nowak ◽  
Michał Tkocz

Pośród pacjentów z rakiem pęcherza moczowego przerzuty do mózgu są rzadko spotykane i dotyczą około 1–7% chorych z naciekającym rakiem pęcherza. W większości przypadków przerzuty mózgowe są wtórne do obecnych już przerzutów w narządach trzewnych i węzłach chłonnych. Pierwotna manifestacja raka przejściowokomórkowego (<i>transitional cell carcinoma</i> – TCC) jako pojedynczy przerzut móżdżkowy została opisana w pojedynczych artykułach. Mężczyzna 55-letni zgłosił się do szpitala z powodu uporczywych dolegliwości bólowych głowy z towarzyszącymi nudnościami. Objawom towarzyszyły zaburzenia równowagi. Tomografia komputerowa (TK) głowy wykazała obecność zmiany guzowatej o wymiarach 28 x 24 x 22 mm w górnej części robaka móżdżku. Badanie TK klatki piersiowej, jamy brzusznej i miednicy małej uwidoczniło zmianę guzowatą w obrębie pęcherza moczowego z poszerzeniem układu kielichowo-miedniczkowego nerki prawej. Nie stwierdzono powiększonych węzłów chłonnych ani cech innych przerzutów. Wykonano kraniotomię i zewnętrzny drenaż komór mózgu, usuwając guz. Pacjenta zakwalifikowano do przezcewkowej elektroresekcji zmiany guzowatej w obrębie pęcherza. Guz obejmował część trójkąta pęcherza moczowego wraz z ujściem prawego moczowodu i większą część prawej ściany pęcherza. Badania histopatologiczne i immunohistochemiczne obu tkanek guzowatych (móżdżku i pęcherza) potwierdziły obecność komórek raka przejściowokomórkowego o wysokim stopniu złośliwości (<i>high grade</i> – HG) z inwazją mięśniową w obrębie wypieracza pęcherza (T2, HG). Na tej podstawie u chorego rozpoznano naciekającego raka pęcherza z przerzutem do móżdżku. Pacjent nie wyraził zgody na cystektomię i został przekazany na oddział onkologii, gdzie zakwalifikowano go do radioterapii głowy i miednicy oraz następowej chemioterapii. W pracy opisano przypadek rozległego guza pęcherza moczowego T2, który rozwinął się bez typowych objawów urologicznych.


Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1819
Author(s):  
Yu-De Chu ◽  
Kwong-Ming Kee ◽  
Wey-Ran Lin ◽  
Ming-Wei Lai ◽  
Sheng-Nan Lu ◽  
...  

Unexpected high risk of synchronous/metachronous hepatocellular carcinoma (HCC) and transitional cell carcinoma (TCC) co-occurrence has been discovered previously. Here, we searched for genetic variation contributing to the co-occurrence of this double primary cancer (DPC). Using targeted exome sequencing, a panel of variants associated with concurrent DPC was identified. However, only a nonsynonymous variant within the Spectrin Repeat Containing Nuclear Envelope Protein 1 (SYNE1) gene was associated with DPC occurrence (p = 0.002), compared with that in the healthy population. Further independent cohort verification analysis revealed that the SYNE1-rs9479297-TT genotype (versus TC + CC genotypes) was enriched in patients with DPC, compared with that in those with TCC alone (p = 0.039), those with HCC alone (p = 0.006), those with non-HCC/non-TCC (p < 0.001), and healthy population (p < 0.001). SYNE1 mRNA expression reduced in both patients with HCC and TCC, and its lower expression in HCC was associated with shorter recurrence-free (p = 0.0314) and metastasis-free (p = 0.0479) survival. SYNE1-rs9479297 genotypes were correlated with tissue SYNE1 levels and clinical outcomes in HCC patients. Finally, SYNE1 silencing enhanced the cell proliferation and migration of HCC/TCC cells. In conclusion, SYNE1-rs9479297 genotypes were associated with HCC/TCC DPC co-occurrence and correlated with SYNE1 expression, which in turn contributed to HCC/TCC cell proliferation and migration, thereby affecting clinical outcomes.


2021 ◽  
Vol 42 (2) ◽  
pp. 103-109
Author(s):  
Weerawut Promwattanapan ◽  
◽  
Nattapong Wongwattanasatien ◽  

Objective: To determine the incidence of incidental prostatic adenocarcinoma and transitional cell carcinoma (TCC) involvement of the prostate gland in patients undergoing radical cystoprostatectomy in Rajavithi Hospital, Secondly, to assess the possible influence of the patient factors and bladder cancer on the pathological findings of the prostate gland. Materials and Methods: We retrospectively reviewed 169 male patients who had undergone radical cystoprostatectomy for bladder cancer between April 2013 and August 2019. Pathologic findings of the prostate gland and urothelial cancer in the prostate gland were catalogued. Information including age, body mass index (BMI), underlying disease, glomerular filtration rate (GFR), pathologic stage, and grade was collected and analyzed to determine any correlations. Results: Incidental prostatic adenocarcinoma and TCC involvement of the prostate gland were found in 15 patients (8.9%) and 29 patients (17.2%), respectively. There were no correlations between patient demographics and pathological findings of the prostate gland. Conclusion: Although the incidence of incidental prostatic adenocarcinoma and TCC involvement of the prostate gland in our research is low, the screening of every candidate for prostate sparing cystectomy with a digital rectal examination, prostate-specific antigen, and transurethral biopsy of the prostatic urethra and bladder neck prior to surgery are recommended.


2021 ◽  
Vol 22 (22) ◽  
pp. 12289
Author(s):  
Suhayla Alnajjar ◽  
Ingo Nolte ◽  
Annegret Becker ◽  
Jan Torben Schille ◽  
Nares Trakooljul ◽  
...  

Claudin (CLDN) proteins are commonly expressed in cancers and targeted in novel therapeutic approaches. The C-terminal of Clostridium perfringens enterotoxin (C-CPE) efficiently binds several claudins. In this study, recombinant C-CPE conjugated to gold nanoparticles (AuNPs) has been used for prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) cell killing in vitro using gold-nanoparticle-mediated laser perforation (GNOME-LP). A PAC and TCC cell lines, as well as red fluorescence variants, allowing deep tissue imaging, were used. CLDN-3, -4, and -7 expression was confirmed by qPCR and immunofluorescences. The binding of C-CPE-AuNPs complexes on the cell surface was examined by scanning electron microscopy (SEM). Further, transcriptome analysis was carried out to evaluate the effect of C-CPE binder on the biological response of treated cells. Directed C-CPE-AuNP binding verified the capability to target CLDN receptors. Transcriptome analysis showed that C-CPE binding may activate immune and inflammatory responses but does not directly affect cell survival. Cancer cells ablation was demonstrated using a combination of GNOME-LP and C-CPE-AuNPs treatment reducing tumor cell viability to less than 10% depending on cell line. The fluorescent cell lines and the verified proof of concept in vitro provide the basis for perspective xenograft studies in an animal model.


Sign in / Sign up

Export Citation Format

Share Document